Tags : Boehringer

M&A

Boehringer Ingelheim to Acquires Labor Dr. Merk & Kollegen for

Shots: The acquisition will enable Boehringer Ingelheim to expand and accelerate its comprehensive program for the development of ATMP-based immuno-oncology therapies including the VSV with modified GP platform and cancer vaccines platforms The addition of Labor Dr. Merk & Kollegen’s site will enable Boehringer Ingelheim to further strengthen its oncolytic virus and cancer vaccine development […]Read More

Weekly Snapshot

PharmaShots Weekly Snapshot (Oct 12-16, 2020)

Novartis’s Luxturna (voretigene neparvovec) Receives Health Canada Approval as the First Gene Replacement Therapy for Inherited Retinal Disease Published: Oct 15, 2020 | Tags: approval, Canada, health, Inherited Retinal Disease, Luxturna, Novartis, receives, voretigene neparvovec Galapagos & Servier’s GLPG1972/S201086 Fails to Meet its Primary Endpoint in P-II ROCCELLA Study for Knee Osteoarthritis Published: Oct 15, […]Read More

Regulatory

Boehringer Ingelheim’s Ofev (nintedanib) Receives FDA’s Advisory Committee Recommendation for

Shots: The FDA’s Arthritis Advisory Committee recommended (10-7 vote) to approve Ofev for the treatment of systemic sclerosis-associated interstitial lung disease (SSc-ILD) The FDA’s recommendation is based on P-III SENSCIS study assessing Ofev vs PBO in 576 patients SSc-ILD resulted in a reduction in loss of pulmonary function by 44% and @52wks. rate of decline […]Read More

Pharma

NMPA, China Accepts NDA for BeiGene & Boehringer BioChina’s Tislelizumab

Shots:  Boehringer Ingelheim (BI) and BeiGene are in collaboration since 2013 for the development of tislelizumab BI BioXcellence is providing CMC services and also helping BeiGene with process & analytical method, supply of GMP clinical material, and CMC filing support with the NMPA Boehringer claims to provide manufacturing support to BeiGene for tislelizumab for global […]Read More